Investor Relations

Latest News

Sep 13, 2021

DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

View Press Release

Sep 7, 2021

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

Aug 11, 2021

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results

View All News

DiaMedica Corporate Presentation

View Presentation

Sep 20 – Sep 23, 2021

Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

View All

Sep 29 – Sep 30, 2021

Piper Sandler Heartland Summit

View All

Nov 2 – Nov 7, 2021

ASN Kidney Week 2021

View All

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

View Board of Directors

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447